Eikon Therapeutics, Inc. Common Stock Stock Analysis & AI Score
Eikon Therapeutics, Inc. Common Stock (EIKN) has an ST Score of 39.6 (C), driven by its Profitability (B) and held back by its Momentum (D-). Analysts rate it Sell with a $5.00 price target (-39.7% downside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Eikon Therapeutics, Inc. Common Stock (EIKN) has an ST Score of 39.6 (C), driven by its Profitability (B) and held back by its Momentum (D-). Analysts rate it Sell with a $5.00 price target (-39.7% downside).
- Strongest
- ProfitabilityB
- Weakest
- MomentumD-
All factor grades
- ProfitabilityB
- Financial StrengthB-
- ValuationC+
- ForecastC-
- GrowthD+
- MomentumD-
Contact
EIKN stock: frequently asked questions
What is EIKN's ST Score?
Eikon Therapeutics, Inc. Common Stock (EIKN) has an ST Score of 39.6 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is EIKN a buy, hold, or sell?
Analysts rate EIKN a Sell, with a price target of $5.00 (-39.7% vs the current price). Our ST Score grades it C (39.6/100). The ST Score is a data-driven signal, not a recommendation.
What are EIKN's factor grades?
Valuation C+, Profitability B, Financial Strength B-, Momentum D-, Growth D+, Forecast C-.
What is EIKN's valuation grade?
Eikon Therapeutics, Inc. Common Stock (EIKN) earns a valuation grade of C+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is EIKN's growth grade?
Eikon Therapeutics, Inc. Common Stock (EIKN) earns a growth grade of D+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is EIKN's profitability grade?
Eikon Therapeutics, Inc. Common Stock (EIKN) earns a profitability grade of B, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is EIKN's financial strength grade?
Eikon Therapeutics, Inc. Common Stock (EIKN) earns a financial strength grade of B-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for EIKN?
The average analyst price target for Eikon Therapeutics, Inc. Common Stock (EIKN) is $5.00 from 1 analysts, which is -39.7% versus the recent price of $8.29.